MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that pre-clinical data characterizing the bioavailability and mechanism of action of omacetaxine mepesuccinate (formerly known as Ceflatonin®) were presented on Monday local time at the American Association of Cancer Research (AACR) 99th Annual Meeting in San Diego, California.
